| Literature DB >> 35956731 |
Aijun Qiu1, Yunyun Wang2, Genlin Zhang2, Hebin Wang1.
Abstract
In recent years, natural polysaccharides have been considered as the ideal candidates for novel drug delivery systems because of their good biocompatibility, biodegradation, low immunogenicity, renewable source and easy modification. These natural polymers are widely used in the designing of nanocarriers, which possess wide applications in therapeutics, diagnostics, delivery and protection of bioactive compounds or drugs. A great deal of studies could be focused on developing polysaccharide nanoparticles and promoting their application in various fields, especially in biomedicine. In this review, a variety of polysaccharide-based nanocarriers were introduced, including nanoliposomes, nanoparticles, nanomicelles, nanoemulsions and nanohydrogels, focusing on the latest research progress of these nanocarriers in the treatment of diabetes and the possible strategies for further study of polysaccharide nanocarriers.Entities:
Keywords: diabetes; drug delivery system; nanocarriers; natural polysaccharides
Year: 2022 PMID: 35956731 PMCID: PMC9370904 DOI: 10.3390/polym14153217
Source DB: PubMed Journal: Polymers (Basel) ISSN: 2073-4360 Impact factor: 4.967
Figure 1Advantages of natural polysaccharide based nano drug delivery system.
Figure 2The structure of chitosan.
Figure 3The structures of α-D-glucan and β-D-glucan.
Figure 4The structure of pectin.
Figure 5The structure of alginate.
Figure 6Chemical structure of hyaluronic acid.
Figure 7Structure of amylose and amylopectin.
Figure 8Structure of cellulose.
Figure 9Polysaccharide-based nanocarriers.
Polysaccharide-based nanocarriers for the entrapment of drugs and used against diabetes.
| Polysaccharide | Nanocarriers | Drug | Drug | Encapsulation | Particles | Zeta | Testing | Ref |
|---|---|---|---|---|---|---|---|---|
| ALG | NPs | INS | 10.8 | 49.6 | 201.8 | −35.7 | SC | [ |
| ALG | NPs | INS | 11.7~38.9 | / | 40~150 | −88~−21.2 | In vitro | [ |
| ALG | NPs | INS | 3.2~3.5 | 77.2~79.2 | 202~279.5 | −34.3~+14.6 | PO | [ |
| ALG | NPs | INS | / | 22,85 | 78,91 | −27.3, −17.1 | PO | [ |
| ALG | Emulsions | Metformin | 3.1 | 78 | 60~150 | +27.3 | PO | [ |
| ALG/CS | NPs | Metformin | / | 10.0~21.6 | 701~989 | −29.8~+5.5 | PO | [ |
| ALG/CS | NPs | Berberine | 8.6 | 85.7 | 202.2 | −14.8 | PO | [ |
| ALG/CS | NPs | Liraglutide | 54.2 | 92.5 | 100 | / | PO | [ |
| ALG/CS | Emulsions | INS | / | 47.3 | 488 | −62.25 | PO | [ |
| ALG/CS | NPs | INS | 7.5~13.9 | 78.9~83.3 | 797~4895 | / | In vitro | [ |
| ALG/CS | NPs | INS | / | 85 | 100~200 | +9.62~+16.42 | PO | [ |
| ALG/CS | NPs | Quercetin | 59 | 95 | 91.58 | −24.63 | PO | [ |
| ALG/CS | NPs | INS | 17.25 | 97 | 90~110 | +38.5 | PO | [ |
| ALG/CS | NPs | INS | 10.7, 4.9 | 81.5, 55.2 | 260.1, 224.4 | −55.7, +13.7 | PO | [ |
| ALG/CS/MD | Micelles | Curcumin | 3.3~5.0 | / | / | / | PO | [ |
| ALG/DS | NPs | INS | 10.1 | 72.4 | 313.2 | −30.6 | In vitro | [ |
| ALG/TMC | NPs | INS | 5.4 | 93.2 | 150.8 | / | In vitro | [ |
| ALG/KC | Hydrogel | IASP | / | 19~26 | 2500~2700 | / | In vitro | [ |
| Cellulose | Hydrogel | NCs | / | / | / | / | Cover the wound | [ |
| CMCD/CMC | Hydrogel | INS | 30.0~31.9 | / | / | / | PO | [ |
| CS | NPs | INS | 27.5 | 91.0 | 46.2 | +9.4 | PO | [ |
| CS | Liposomes | INS | / | 85.75 | 439 | +60.5 | PO | [ |
| CS | Liposomes | Curcumin | / | / | 247.6 | +61.5 | In vitro | [ |
| CS | NPs | INS | / | 73.0~85.4 | 204~303.9 | +14.9~+32.1 | PO | [ |
| CS | NPs | INS | / | 49.4~60.9 | 215~255 | +20.7~+30.1 | PO | [ |
| CS | NPs | INS | 47.0 | 52.5 | 551.7 | +25.7 | PO | [ |
| CS | NPs | INS | / | 93.1 | 91.3~220.2 | +14.4 | In vitro | [ |
| CS | NPs | INS | 88.4~98.7 | 88.4~98.7 | 86~257 | +22.1~+26.1 | SC | [ |
| CS | Liposomes | FeSO4 | / | 72.8~82.7 | 209~304 | +27.8~+33.1 | In vitro | [ |
| CS | NPs | INS | 13.4~17.2 | 79.3~82.5 | 39.2~50.6 | +27.8~+49.6 | PO | [ |
| CS | NPs | INS | 35.8~33.0 | 72.4~78.2 | 217.6~237.0 | +8.5~+15.6 | PO | [ |
| CS | Liposomes | INS | 10.7 | / | 100~150 | −40~+40 | PO | [ |
| CS | Hydrogel | BSA | 9.85~9.91 | 98.63~99.07 | / | / | In vitro | [ |
| CS | NPs | FA | / | 50 | 242 | +32 | In vitro | [ |
| CS | NPs | INS | 18~19 | 68~74 | 218~250 | +25~+27 | In vitro | [ |
| CS | Emulsions | INS | / | / | 8.7~141.9 | +1.2~+33.9 | PO | [ |
| CS | NPs | INS | / | 85 | 200~550 | +2.83~+24.69 | PO | [ |
| CS | NPs | INS | 6.83 | 41 | 252.4 | +5.99 | PO | [ |
| CS | NPs | Exendin-4 | 14.7 | 60.9 | 260~1049 | +3.6~+33.7 | PO | [ |
| CS/fucoidan | Capsules | INS | 8.6 | 56.4 | 256.7 | +26.5 | PO | [ |
| CS/Pectin | NPs | Metformin | / | 60~92 | 581.8 | +41.8 | PO | [ |
| CS/Pectin | Nanogel | TM | / | 27.4 | 175.2 | −10.9 | In vitro | [ |
| Starch | NPs | Plant extract | / | / | 19.8 | / | In vitro | [ |
| Pectin | NPs | Metformin | / | 68 | 482.7 | +38.9 | PO | [ |
| HA | NPs | / | / | / | 221.0 | −25.7 | IV | [ |
| HA | NPs | CD44 siRNAs | / | / | 223.1 | −25.6 | IP | [ |
| HA/CS | NPs | INS | 8.3 | 95 | 95~200 | −40~−50 | JI | [ |
| Xanthan | Micelles | Glibenclamide | / | 98.8 | 652.8 | −27.6 | PO | [ |
| Gelatin | NPs | INS | / | 11.7~49.7 | 50~250 | / | In vitro | [ |
| Dextran | Polymersome | INS | 2.2~27.8 | 44.2~92.5 | 123.5~342.3 | / | PO | [ |
| Dextran | NPs | INS | / | 48.68 | 48~74 | / | In vitro | [ |
| CS/GA | NPs | Glycyrrhizin | / | 99.84 | 181.4 | +31.4 | PO | [ |
| CMCS | NPs | INS | 9.8 | 67 | 100~300 | / | PO | [ |
| Pullulan | Hydrogel | INS | 1.9~12.2 | / | / | / | In vitro | [ |
| Pullulan | Hydrogel | acarbose | / | 63 | / | / | In vitro | [ |
| TMC | Micelles | INS | 12.0~14.2 | 82.2~90.3 | 106.8~149.8 | −19.1~+25.4 | PO | [ |
| CS/HPMCP | NPs | INS | 17.6~48.4 | 87.8~90.9 | 168~239 | −26.7~+19.5 | PO | [ |
| CS/β-CD | Hydrogel | INS | / | / | / | / | PO | [ |
| CMCD-g-CS | NPs | INS | 0.13 | 57.0 | 144~297 | / | PO | [ |
| NTC | NPs | INS | 7.8 | 47.0 | 247.6 | +45.2 | PO | [ |
| NSC | Hydrogel | INS | 38 | 76 | / | / | PO | [ |
| β-CD | Nanogel | INS/pCMV-Ins | 8.4 | 84.4 | 164~240 | +23~+46.3 | In vitro | [ |
| SCG | NPs | INS | 2.5~3.5 | 53.9~70.2 | 60~200 | −2.0~−6.5 | PO | [ |
| Salecan | NPs | INS | / | 30.3~60.8 | / | / | PO | [ |
Abbreviations: CMCD/CMC: Carboxymethyl β-cyclodextrin grafted carboxymethyl chitosan, BSA: bovine serum albumin, CMCD-g-CS: carboxymethyl-β-cyclodextrin-grafted chitosan, CMCS: carboxymethyl chitosan, DS: dextran sulfate, FA: Ferulic acid, KC: κ-carrageenan, GA: gum Arabic, IASP: Insulin aspart, SCG: short-chain glucan, FD: fucoidan, MD: maltodextrin, TM: Timolol maleate, TMC: Trimethyl chitosan, HPMCP: hydroxy-propyl methylcellulose phthalate, NTC: N-trimethyl chitosan chloride, NSC: N-succinyl chitosan, NCs: Nanobiocomposites, SC: Subcutaneous injection, IV: intravenous injection, JI: Jejunal instillations, PO: per os, INS: Insulin.